Document is current

Article History

Received: 14 February 2024

Accepted: 10 April 2024

First Online: 9 May 2024

Declarations

:

: Luis A. Vázquez is advisory board member for Eli Lilly, has received speaker honoraria from AstraZeneca, Eli Lilly, and Novo Nordisk, has received research grants to institution from Eli Lilly, Novartis and Novo Nordisk, and is minor shareholder of Eli Lilly. Santiago Tofé-Povedano has received consulting, speaker and research honoraria from Eli Lilly, Novo Nordisk, AstraZeneca and GlaxoSmithKline. Diego Bellido-Guerrero is advisory board member for Eli Lilly, Novo Nordisk, Sanofi, Nestle HS, Persan Pharma, has received speaker honoraria from Novo Nordisk, Sanofi, Eli Lilly, Boehringer, Persan Pharma, Nutricia, AstraZeneca and is collaborator in national health research projects (FIS) and has participated in clinical trials of Eli Lilly, Sanofi, Bayer, Adventia Pharma, AstraZeneca, Novartis, Abbott. M.B.S has participated in clinical trials and has received speaker honoraria from Eli Lilly, Novo Nordisk, Abbot and AstraZeneca. Alfonso Soto-González is advisor on scientific boards for Novo Nordisk and Eli Lilly, has received speaker honoraria from MSD, Novo Nordisk, Eli Lilly and AstraZeneca, is collaborator in national health research projects (FIS) and has participated in clinical trials of Eli Lilly, Novo Nordisk, AstraZeneca, Bayer, Boehringer, Amgen, Pfizer and Novartis. Pedro Mezquita-Raya is advisor on scientific boards for Abbott, AstraZeneca, FAES and Novo Nordisk; lectures for AstraZeneca, Eli Lilly, FAES, Fresenius and Novo-Nordisk and performs research activities for Eli Lilly and Novo Nordisk. Elías Delgado has received unrestricted research support from AstraZeneca, Novo Nordisk, Sanofi, Pfizer, and Roche and has received consulting fees and/or honoraria for membership on advisory boards and speaker´s bureau from AstraZeneca, Novo Nordisk, Lilly, Sanofi, GlaxoSmithKline, Pfizer, Almirall, Novartis, Abbott Laboratories, Esteve, and Merck Sharp & Dohme. Carmen Fajardo-Montañana has received speaker honoraria from Eli Lilly and has participated in clinical trials of Eli Lilly. Cristóbal Morales-Portillo is advisor on scientific boards for Novo Nordisk, Lilly, MSD, Boehringer, Astra, Sanofi, Abbot; has received speaker honoraria from Sanofi, Novo Nordisk, AstraZeneca, Roche, Lilly, Boehringer, MSD, Ferrer, Janssen, Abbot; and has participated in clinical trials of Novo Nordisk, Sanofi, AstraZeneca, Pfizer, Lilly, Merck, Lexicon, FPS, Hanmi, Janssen Boehringer, Takeda, Roche, Theracos, LeeGanz. Miriam Rubio-de Santos and Irene Romera are employees of Eli Lilly. Ana Causanilles works for an independent scientific consultancy (Outcomes’10) that has received honoraria for conducting the study and writing the current manuscript. Esteban Jódar-Gimeno has received consulting honoraria from Amgen, AstraZeneca, Eli Lilly, FAES, GSK, Italfármaco, MSD, Mundipharma, Novo Nordisk, has participated in clinical research for Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, GSK, Janssen, MSD, Novo Nordisk, Pfizer, Sanofi, and has received speaker honoraria from Amgen, Asofarma, AstraZeneca, Boehringer Ingelheim, Eli Lilly, FAES, MSD, Novartis, Novo Nordisk, Sanofi, Tecnofarma, ZP Pharmaceuticals.

: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.